Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Newamsterdam Pharma Company N.V. (NAMS)

Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,362,310
  • Shares Outstanding, K 92,386
  • Annual Sales, $ 14,090 K
  • Annual Income, $ -176,940 K
  • EBIT $ -183 M
  • EBITDA $ -183 M
  • 60-Month Beta 0.06
  • Price/Sales 171.72
  • Price/Cash Flow N/A
  • Price/Book 4.51

Options Overview Details

View History
  • Implied Volatility 55.68% ( -6.31%)
  • Historical Volatility 126.80%
  • IV Percentile 8%
  • IV Rank 11.15%
  • IV High 254.50% on 11/13/24
  • IV Low 30.73% on 08/05/24
  • Put/Call Vol Ratio 0.86
  • Today's Volume 270
  • Volume Avg (30-Day) 829
  • Put/Call OI Ratio 1.18
  • Today's Open Interest 22,463
  • Open Int (30-Day) 15,274

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.50
  • Number of Estimates 5
  • High Estimate -0.46
  • Low Estimate -0.53
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.61 +43.61%
on 12/05/24
27.29 -7.33%
on 12/11/24
+0.53 (+2.14%)
since 11/12/24
3-Month
15.19 +66.49%
on 09/25/24
27.29 -7.33%
on 12/11/24
+9.29 (+58.06%)
since 09/12/24
52-Week
9.61 +163.16%
on 12/13/23
27.29 -7.33%
on 12/11/24
+15.43 (+156.49%)
since 12/12/23

Most Recent Stories

More News
NewAmsterdam Pharma Prices $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma announces $416.5 million public offering of ordinary shares and pre-funded warrants to support cardiovascular treatments.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a clinical...

NAMS : 25.50 (-0.27%)
NewAmsterdam Pharma Reports Positive Phase 3 Results for Obicetrapib in Lowering LDL-C and Reducing Cardiovascular Events

NewAmsterdam reports positive Phase 3 results for obicetrapib, showing significant LDL-C reduction and favorable safety profile compared to placebo.Quiver AI SummaryNewAmsterdam Pharma Company has reported...

NAMS : 25.50 (-0.27%)
NewAmsterdam Pharma Grants Inducement Share Options to New Non-Executive Hires

NewAmsterdam Pharma grants 79,000 share options to new hires as employment inducement under its 2024 Inducement Plan.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical firm...

NAMS : 25.50 (-0.27%)
NewAmsterdam Pharma Reports Significant Efficacy and Safety Results in Phase 3 BROOKLYN Trial of Obicetrapib for Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma reports significant LDL-C and Lp(a) reductions with obicetrapib in Phase 3 trial, maintaining safety comparable to placebo.Quiver AI SummaryNewAmsterdam Pharma Company announced positive...

NAMS : 25.50 (-0.27%)
Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday

The company announced a stock sale to help fund operations.

NAMS : 25.50 (-0.27%)
EQT Life Sciences closes Dementia Fund at the hard cap

The LSP Dementia Fund has held its final close at approximately EUR 260 million, at the hard cap and above its original target fund size of EUR 100 million...

NAMS : 25.50 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

NewAmsterdam Pharma Holding B.V. is a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases. NewAmsterdam Pharma Holding B.V., formerly known as Frazier Lifesciences Acquisition Corporation, is based in MENLO PARK, Calif....

See More

Key Turning Points

3rd Resistance Point 29.92
2nd Resistance Point 28.60
1st Resistance Point 27.09
Last Price 25.50
1st Support Level 24.26
2nd Support Level 22.94
3rd Support Level 21.43

See More

52-Week High 27.29
Last Price 25.50
Fibonacci 61.8% 20.54
Fibonacci 50% 18.45
Fibonacci 38.2% 16.36
52-Week Low 9.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar